| 1. | https://www.klug-entscheiden.com/einfuehrung/konsensus-kommission-ke (last accessed on XX Xxxxxxx XXXX). |
| 2. | https://www.klug-entscheiden.com/empfehlungen/uebersicht (last accessed on XX Xxxxxxx XXXX). |
| 3. | Bhandari S, Mehta S, Khwaja A, et al.: Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 2022; 387: 2021–32. |
| 4. | Fu EL, Evans M, Clase CM, et al.: Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol 2021; 32: 424– 35. |
| 5. | Qiao Y, Shin JI, Chen TK, et al.: Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 2020; 180: 718–26. |
| 6. | European Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. Lancet Public Health 2022; 7: e897–913. |
| 7. | Chong Y, Shimoda S, Miyake N, et al.: Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis. Infect Drug Resist 2017; 10: 193–9. |
| 8. | Vehreschild MJ, Hamprecht A, Peterson L, et al.: A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69: 3387–92. |
| 9. | Classen AY, Henze L, von Lilienfeld-Toal M, et al.: Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021; 100: 1603–20. |
| 10. | Thorpe A, Sirota M, Juanchich M, et al.: Action bias in the public’s clinically inappropriate expectations for antibiotics. J Exp Psychol Appl 2020; 26: 422–31. |
| 11. | Cometta A, Kern WV, De Bock R, et al.: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382–9. |
| 12. | Wu CW, Wu JY, Chen CK, et al.: Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Supportive Care Cancer 2015; 23: 2863–72. |
| 13. | Heinz WJ, Buchheidt D, Christopeit M, et al.: Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017; 96: 1775–92. |
| 14. | Hansson C, Hoborn J, Möller A, et al.: The microbial flora in venous leg ulcers without clinical signs of infection. Repeated culture using a validated standardised microbiological technique. Acta Dermato-Venereologica 1995; 75: 24–30. |
| 15. | Matkoski C, Sharp SE, Kiska DL: Evaluation of the Q score and Q234 systems for cost-effective and clinically relevant interpretation of wound cultures. J Clin Microbiol 2006; 44: 1869–72. |
| 16. | Chakraborti C, Le C, Yanofsky A: Sensitivity of superficial cultures in lower extremity wounds. J Hosp Med 2010; 5: 415–20. |
| 17. | Gardner SE, Haleem A, Jao YL, et al.: Cultures of diabetic foot ulcers without clinical signs of infection do not predict outcomes. Diabetes Care 2014; 37: 2693–701. |
| 18. | Lipsky BA, Senneville É, Abbas ZG, et al.: International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36 (Suppl 1): e3280. |
| 19. | Marchand-Senécal X, Brasg I, Kozak R, et al.: Impact of Rejection of Low-Quality Wound Swabs on Antimicrobial Prescribing: A Controlled Before-After Study. Open Forum Infect Dis 2020; 8: ofaa609. |
| 20. | Camilleri Attard F, Gatt A, Formosa C: Superficial tissue swabs versus deep tissue samples in the detection of microbiological profile of infected diabetic foot ulcerations. Int J Low Extr Wounds 2021; DOI 10.1177/15347346211053481. |
| 21. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373–498. |
| 22. | Eckardt L, Wolfes J, Frommeyer G: Benefits of early rhythm control of atrial fibrillation. Trends Cardiovasc Med 2023; 11: S1050–1738(23)00041–5. |
| 23. | Kirchhof P, Camm AJ, Goette A, et al.: Early rhythm-control therapy in patients with atrial fibrillation. N Eng J Med 2020; 383: 1305–16. |
| 24. | Willems S, Bororf K, Brandes A, et al.: Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 1219–30. |
| 25. | Eckardt L, Sehner S, Sulig A, et al.: Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 4127–414. |
| 26. | Andrade JG, Wells GA, Deyell MW, et al.: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Eng J Med 2021; 384: 305–15. |
| 27. | Wazni OM, Dandamudi G, Sood N, et al.: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Eng J Med 2021; 384: 316–24. |
| 28. | Borch JE, Andersen KE, Bindslev-Jensen C: The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol 2006; 98: 357–62. |
| 29. | Shenoy ES, Macy E, Rowe T, et al.: Evaluation and Management of Penicillin Allergy: A Review. JAMA 2019; 321: 188–99. |
| 30. | Blumenthal KG, Peter JG, Trubiano JA, et al.: Antibiotic allergy. Lancet 2019; 393: 183–98. |
| 31. | West RM, Smith CJ, Pavitt SH, et al.: ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic pre- scribing and health outcomes. J Antimicrob Chemother 2019; 74: 2075–82. |
| 32. | Lee CE, Zembower TR, Fotis MA, et al.: The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160: 2819–22. |
| 33. | Blumenthal KG, Kuper K, Schulz LT, et al.: Association Between Penicillin Allergy Documentation and Antibiotic Use. JAMA Intern Med 2020; 180: 1120–2. |
| 34. | Blumenthal KG, Lu N, Zhang Y, et al.: Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018; 361: k2400. |
| 35. | Macy E, Contreras R: Health care use and serious infection prevalence associated with penicillin „allergy“ in hospitalized patients: A cohort study. J Allergy Clin Immunol 2014; 133: 790–6. |
| 36. | Perez-Encinas M, Lorenzo-Martínez S, Losa-García JE, et al.: Impact of Penicillin Allergy Label on Length of Stay and Mortality in Hospitalized Patients through a Clinical Administrative National Dataset. Int Arch Allergy Immunol 2022; 183: 498–506. |
| 37. | Huang KG, Cluzet V, Hamilton K, et al.: The Impact of Reported Beta-Lactam Allergy in Hospitalized Patients With Hematologic Malignancies Requiring Antibiotics. Clin Infect Dis 2018; 67: 27–33. |
| 38. | Kaminsky LW, Ghahramani A, Hussein R, et al.: Penicillin Allergy Label Is Associated With Worse Clinical Outcomes in Bacterial Pneumonia. J Allergy Clin Immunol Pract 2022;10: 3262–9. |
| 39. | S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus.AWMF-Registernummer 092/001 – update 2018. https://register.awmf.org/de/leitlinien/detail/092–001 (last accessed on 26 April 2023). |
| 40. | Trubiano JA, Vogrin S, Chua KYL, et al.: Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine 2020;180: 745–52. |
| 41. | Copaescu AM, Vogrin S, James F, et al.: Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med 2023; 183: 944–52. |
| 42. | Piotin A, Godet J, Trubiano A, et al.: Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol 2022; 128: 27–32. |
| 43. | Koch T, Leubner H, Brehm T, Witte J: Penicillinallergie: Sicher und effektiv ausschließen. Dtsch Arztebl 2023; 120: A-822/B-699. |
| 44. | Rinella ME, Lazarus JV, Ratziu V, et al.: A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966–86. |
| 45. | Ward ZJ, Bleich SN, Cradock AL, et al.: Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381: 2440–50. |
| 46. | Estes C, Razavi H, Loomba R, et al.: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67: 123–33. |
| 47. | Huang DQ, Wilson LA, Behling C, et al.: Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology 2023; 165: 463–72.e5. |
| 48. | Koutoukidis DA, Koshiaris C, Henry JA, et al.: The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021; 115: 1544–55. |
| 49. | Roeb E, Canbay A, Bantel H, et al.: Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) April 2022 – AWMF-Registernummer: 021-025. |
| 50. | Hannah WN Jr, Harrison SA: Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016; 20: 339–50. |
| 51. | Hall KD, Ayuketah A, Brychta R, et al.: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab 2019; 30: 67–77.e3. Erratum in: Cell Metab 2019; 30: 226 and Cell Metab 2020; 32: 690. |
| 52. | Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E: Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021; 13: 1442. |
| 53. | Malik VS, Hu FB: The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. Nat Rev Endocrinol 2022; 18: 205–18. |
| 54. | Newsome PN, Buchholtz K, Cusi K, et al.: A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384: 1113–24. |
| 55. | Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.: Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367–78.e5. |
| 56. | Promrat K, Kleiner DE, Niemeier HM, et al.: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129. |
| 57. | Keating SE, Hackett DA, George J, et al.: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157–66. |
| 58. | Johnson NA, Sachinwalla T, Walton DW, et al.: Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105–12. |
| 59. | Hashida R, Kawaguchi T, Bekki M, et al.: Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 2017; 66: 142–52. |
| 60. | Fernández T, Viñuela M, Vidal C, et al.: Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One 2022; 17: e0263931. |
| 61. | Verrastro O, Panunzi S, Castagneto-Gissey L, et al.: Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401: 1786–97. |
Klug entscheiden in der Hämatologie und Medizinischen Onkologie
Literaturnachweise 2024
Literaturnachweise 2023
| 1. | Klug entscheiden – Eine Initiative der Deutschen Gesellschaft für Innere Medizin (DGIM). Deutsches Ärzteblatt 2021; 118: Sammelband April 2021. https://www.klug-entscheiden.com/fileadmin/user_upload/2021_Sammelband_Klug_entscheiden_Web_final.pdf (last accessed 13 April 2023). |
| 2. | https://dgim.de/veroeffentlichungen/klug-entscheiden/ (last accessed 13 April 2023). |
| 3. | Singh P, Arora A, Strand TA, et al.: Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 823–36 CrossRef MEDLINE |
| 4. | Palmieri B, Vadala M, Laurino C: Gluten-free diet in non-celiac patients: beliefs, truths, advantages and disadvantages. Minerva Gastroenterol Dietol 2019; 65: 153–62. CrossRef MEDLINE |
| 5. | Melini V, Melini F: Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients 2019; 11: 170. CrossRef MEDLINE PubMed Central |
| 6. | Leonard MM, Sapone A, Catassi C, et al.: Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647–56. CrossRef MEDLINE |
| 7. | Welstead L: The Gluten-Free Diet in the 3rd Millennium: Rules, Risks and Opportunities. Diseases 2015; 3: 136–49. CrossRef MEDLINE PubMed Central |
| 8. | Felber J, Bläker H, Fischbach W, et al.: Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 790–856. CrossRef MEDLINE |
| 9. | Castellsague J, Riera-Guardia N, Calingaert B, et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127–46. CrossRef MEDLINE PubMed Central |
| 10. | Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801. CrossRef MEDLINE |
| 11. | Gonzalez-Perez A, Saez ME, Johansson S, et al.: Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768. CrossRef MEDLINE PubMed Central |
| 12. | Fischbach W, Bornschein J, Hoffmann JC, et al.: Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juli 2022 – AWMF-Registernummer: 021 – 001. https://register.awmf.org/assets/guidelines/021-001l_S2k_Helicobacter-pylori-gastroduodenale-Ulkuskrankheit_2022-07_1.pdf (last accessed 13 April 2023). |
| 13. | Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413–16. CrossRef MEDLINE |
| 14. | Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–99. CrossRef MEDLINE |
| 15. | Crooks CJ, West J, Card TR: Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384–93. CrossRef MEDLINE PubMed Central |
| 16. | Weil J, Langman MJ, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31. CrossRef MEDLINE PubMed Central |
| 17. | Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24. CrossRef MEDLINE |
| 18. | Fischbach W: Medikamenteninduzierte gastrointestinale Blutung. Internist. 2019; 60: 597–607. CrossRef MEDLINE |
| 19. | Jarupongprapa S, Ussavasodhi P, Katchamart W: Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830–38. CrossRef MEDLINE |
| 20. | Rostom A, Muir K, Dube C, et al.: Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47–71. CrossRef MEDLINE PubMed Central |
| 21. | Scally B, Emberson JR, Spata E, et al.: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231–41. CrossRef MEDLINE |
| 22. | Wang X, Tian HJ, Yang HK, et al.: Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876–80. CrossRef MEDLINE |
| 23. | Rane PP, Guha S, Chatterjee S, et al.: Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm 2017; 13: 358–63. CrossRef MEDLINE |
| 24. | Hoffmann F, Glaeske G, Schmiemann G: Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über die Jahre 2005-2013. Z Gastroenterol 2015; 53: 95–100. CrossRef MEDLINE |
| 25. | Haastrup PF, Thompson W, Søndergaard J, et al.: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123: 114–21. CrossRef MEDLINE |
| 26. | Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022; 162: 1334–42. CrossRef MEDLINE |
| 27. | Beschluss der Bundesärztekammer über die Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. Dtsch Arztebl 2020; 117 (40): A-1883/B-1603. VOLLTEXT |
| 28. | Carson JL, Sieber F, Cook DR, et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385 (9974): 1183–89. CrossRef MEDLINE |
| 29. | Carson JL, Stanworth SJ, Denis JA, et al.: Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12 (12): CD002042 CrossRef MEDLINE PubMed Central |
| 30. | Berger MD, Gerber B, Arn K, et al.: Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012; 97: 116–22. CrossRef MEDLINE PubMed Central |
| 31. | Leahy MF, Trentino KM, May C, et al.: Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96. CrossRef MEDLINE |
| 32. | Amano K, Baracos VE, Hopkinson JB: Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev in Oncol Hematol 2019; 143: 117–23. CrossRef MEDLINE |
| 33. | Tobberup R, Thoresen L, Falkmer UG, et al.: Effects of current parenteral nutrition treatment on health-related quality of life, physical function nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139: 96–107. CrossRef MEDLINE |
| 34. | Arends J, Strasser F, Gonella S, et al.: Cancer cachexia in adult patients: ESMO Clinical Practice. ESMO Open 2021; 6 (3): 100092. CrossRef MEDLINE PubMed Central |
| 35. | Orrevall Y: Nutritional support at the end of life. Nutrition 2015; 31: 615–6. CrossRef MEDLINE |
| 36. | Arends J, Bachmann P, Bracos V, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48 CrossRef MEDLINE |
| 37. | Arends J, Jordan K: Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open 2020; 5 (4): e000831. CrossRef MEDLINE PubMed Central |
| 38. | Raijmakers NJH, van Zuylen L, Costantini M, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2022; 22: 1478–86. CrossRef MEDLINE |
| 39. | Bouleuc C, Anota A, Cornet C, et al.: Impact on Health-related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: results from a Randomized Controlled Trial. Oncologist 2020; 25: e843–51. CrossRef MEDLINE PubMed Central |
| 40. | McCann RM, Hall WJ, Groth-Juncker A: Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263–6. CrossRef MEDLINE |
| 41. | Chow R, Bruera E, Arends J, et al.: Enteral and parenteral nutrition in cancer patients a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer 2020; 28: 979–1010. CrossRef MEDLINE |
| 42. | Collet J-P, Thiele H, Barbato E, et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–367 CrossRef MEDLINE |
| 43. | Thiele H, Bauersachs J, Mehilli J, et al.: Kommentar zu den 2020er-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. Kardiologe 2021; 15: 19–31. CrossRef |
| 44. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498 CrossRef MEDLINE |
| 45. | Rourke EJ: Ten Years of Choosing Wisely to Reduce Low-Value Care. New Engl J Med 2022; 386 (14): 1293–5. CrossRef MEDLINE |
Literaturnachweise
- S3-Leitlinie: Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung. Langversion 1.1 – Mai 2015. AWMF-Registernummer: 128/001OL.
- Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, et al.: Early palliative care for patients with metastatic nonsmall- cell lung cancer. N Engl J Med 2010; 363: 733–42.
- Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, et al.: Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014; 383: 1721–30.
- Gaertner J, Wolf J, Voltz R: Early palliative care for patients with metastatic cancer. Curr Opin Oncol 2012; 24: 357–62.
- Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S: The prevalence of psychological distress by cancer site. Psychooncology 2001; 10: 19–28.
- Schumacher A: Stellenwert der Psychoonkologie im neuen deutschen Gesundheitssystem. Der Onkologe 2004; 10: 98–102.
- Holland JC, Breitbart WS, Jacobsen PB, Lederberg MS, Loscalzo MJ, McCorkle R, Herausgeber. Psycho-Oncology. New York: Oxford University Press; 2010.
- S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1. Januar 2014, AWMF-Registriernummer: 032/051OL.
- Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R: Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. JCO 2013; 31: 782–93.
- Ventafridda V, et al.: A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 850–6.
- Zeppetella G, Davies AN: Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013; 10: CD004311.
- Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D: Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367: 1616–25.
- Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N: A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 2003; 327: 195–8.
- Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22: 315–21.
- Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, et al.: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: Blood 2013; 122: 872–84.
- Shaw A, Kim D, Nakagawa K, Seto T, Crinó L, et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 20; 368: 2385–94.
- Chapman P, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.: BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16.
- Allegra C, Jessup J, Somerfield M, Hamilton SR, Hammond EH, et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091–6.
- Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehension cancer network. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw 2015; 13: 326–62.
- Dührsen U, Michael A. Fridrik MA, Schmitz N: Diffuses großzelliges B-Zell-Lymphom. Leitlinie der DGHO, 2014; www.onkope dia.com/de/onkopedia/guidelines/.
- Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al.: National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas: Version 1.2013. Fort Washington (PA): NCCN.2013.
- Hodgkin Lymphom. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten. Version 1.0, Februar 2013. AWMF Registernummer: 018/029OL.
- Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR: Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk 2010; 10: 270–7.
- Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, et al.: Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 2012; 91: 1741–5.
- Guppy AE, Tebbutt NC, Norman A, Cunningham D: The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 2003; 44: 123–5.
- Dryver ET, Jernström H, Tompkins K, Buckstein R, Imrie KR: Follow-up of patients with Hodgkin’s disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003; 89: 482–6.
- Oscier D, Dearden C, Eren E, Fegan C, Follows G, et al.: British Committee for Standards in Haematology: Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 2012; 159: 541–64.
- Scarfo L, Zibellini S, Tedeschi A, Maura F, Neri A, et al.: Impact of B cell count and imaging screening in cMBL: any need to revise the current guidelines? Leukemia 2012; 26: 1703–7.
- Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, et al.: Limited clinical relevance of imaging techniques in the followup of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 2011; 117: 1817–21.
- Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, et al.: Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 2015; 1: 778–84.
- Azzoli CG, Temin S, Aliff T, et al.: 2011 focused update of 2009 American Society of Oncology clinical practice guideline update on chemotherapy for stage IV non–small cell lung cancer. J Clin Oncol 2011; 29: 3825–31.
- 32. Ettinger DS, Akerley W, Bepler G, et al.: Non-small cell lung cancer. J Natl Compr Canc Netw 2010; 8: 740–801.
- Carlson RW, Allred DC, Anderson BO, et al.: Breast cancer. J Natl Compr Canc Netw 2009; 7: 122–92.
- Engstrom PF, Benson AB 3rd, Chen YJ, et al.: Colon cancer clinical practice guidelines. J Natl Compr Canc Netw 2005; 3: 468–91.
- Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, et al.: Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 2016; 34: 381–6.
- Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, et al.: American Society of Clinical Oncology: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189–98.
- Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, et al.: SHIVA investigators: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proofof- concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16: 1324–34.
- Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, et al.: American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015, 33: 3199–212.
- Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, et al.: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997, 336: 1776–80.